Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
British Journal of Haematology|August 24, 2017
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2018
Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation TherapyChelsea C Pinnix, Laura Cella, Therese Y Andraos, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Head & Neck|April 17, 2019
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
British Journal of Haematology|August 24, 2017
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2018
Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation TherapyChelsea C Pinnix, Laura Cella, Therese Y Andraos, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Head & Neck|April 17, 2019
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Pageof 17